AC
ESPR

Aristeia Capital’s Esperion Therapeutics ESPR Stock Holding History

Aristeia Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-70,959
Closed -$102K – 523
2025
Q1 		$102K Hold
70,959
– – ﹤0.01% 337
2024
Q4 		$156K Hold
70,959
– – 0.01% 284
2024
Q3 		$117K Hold
70,959
– – ﹤0.01% 253
2024
Q2 		$158K Hold
70,959
– – ﹤0.01% 226
2024
Q1 		$190K Hold
70,959
– – ﹤0.01% 172
2023
Q4 		$212K Hold
70,959
– – ﹤0.01% 83
2023
Q3 		$69.5K Hold
70,959
– – ﹤0.01% 127
2023
Q2 		$98.6K Hold
70,959
– – ﹤0.01% 143
2023
Q1 		$113K Hold
70,959
– – ﹤0.01% 231
2022
Q4 		$442K Sell
70,959
-44,992
-39% -$322K 0.01% 323
2022
Q3 		$777K Hold
115,951
– – 0.01% 406
2022
Q2 		$737K Hold
115,951
– – 0.01% 381
2022
Q1 		$538K Hold
115,951
– – 0.01% 396
2021
Q4 		$580K Buy
115,951
+48,258
+71% +$386K 0.01% 429
2021
Q3 		$816K Buy
+67,693
New +$986K 0.02% 354

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Aristeia Capital's ESPR Position: Q2 2025 in Review

Aristeia Capital sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 70,959 shares — an estimated $102K sold.

Aristeia Capital first reported a position in ESPR in Q3 2021 and held it in 15 quarters. The position peaked at $816K in Q3 2021. 163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Aristeia Capital reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Aristeia Capital sold 70,959 Esperion Therapeutics shares in Q2 2025, an estimated $102K.
  • Aristeia Capital first reported a position in Esperion Therapeutics in Q3 2021 and held it in 15 quarters.
  • Aristeia Capital's Esperion Therapeutics position peaked at $816K in Q3 2021.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Aristeia Capital's 13F filing for Q2 2025, filed 14 Aug 2025.